Vitamin B12 with Methylcobalamin is recommended as a treatment for Parkinson’s symptoms. Why? It reduces neurotoxicity and helps reverse symptoms. Research studies report high-dose B12 methylcobalamin inhibits enzymes related to PD, thereby protecting neurons and improving motor/non-motor symptoms.
The bottom line: vitamin B12 supplement plays a leading role in helping to reverse symptoms associated with a diagnosis of Parkinsons.
One of B12’s key roles is helping to maintain myelin, the insulating sheaths covering the nerve endings in the brain, spinal cord, and optic nerve. A lack of sufficient B12 is responsible for faulty sheaths that result in nerve dysfunction. Deficiencies cause issues with neurological conditions including gait, instability and cognitive decline.
There is a two edged sword at play here. People with Parkinsons avoid foods enriched with B12 including meat products because they can interfere with absorption of their medications.
More importantly, levodopa depletes vitamin B12. The positive results when persons on medications take a B12 supplement are supported by research studies posted below.
There are several forms of B12. The natural form known as methylcobalamin is recommended as a therapy for neurological conditions. It has superior absorption. If you are currently taking a B12 supplement make sure it is the methycobalamin form. If not, purchase a B12 supplement that has it
Studies on Vitamin B12 Deficiencies with Parkinsons
J Gerontol A Biol Sci Med Sci. 2026 Mar 14:glag048. Dietary One?Carbon Nutrients and Genetic Risk in Parkinson’s Disease: A Prospective Cohort Study
Abstract
Background: Several studies have investigated the effects of dietary one-carbon metabolism (OCM) nutrients, such as methionine, folate, vitamin B6, and vitamin B12, on Parkinson’s disease (PD). However, current evidence remains insufficient to definitively establish a link between OCM intake, PD incidence, and genetic risk.
Methods: Among 202171 individuals aged 37-73 in the UK Biobank, we assessed dietary OCM nutrient intake via repeated 24?hour recalls, determined PD incidence via validated ICD?10 codes, and quantified genetic risk with polygenic risk scores. Employing Cox proportional hazards models supplemented by sensitivity analyses, we evaluated the associations and potential interactions among OCM nutrient intake, genetic risk, and PD incidence.
Results: Over a median 12.27-year follow-up of 202171 participants, 1037 incident PD cases occurred. In multivariable-adjusted Cox models, compared with participants in the lowest quartile, those in the highest quartile of methionine, vitamin B6, folate, and vitamin B12 had a lower risk of PD [HR (95% CI)=0.83 (0.69-1.00), 0.75 (0.62-0.90), 0.71 (0.59-0.85), and 0.79 (0.65-0.94)]. Genetically-stratified analyses showed folate inversely associated with PD risk in the low-risk group [HR (95% CI)= 0.65 (0.48-0.88)] (P for interaction = 0.48); vitamin B12 linked to lower risk in the high-risk group [HR (95% CI)= 0.78 (0.63-0.99)] (P for interaction = 0.83); and vitamin B6 inversely associated across both strata [high-risk HR (95% CI)= 0.77 (0.62-0.97); low-risk HR (95% CI) = 0.59 (0.44-0.80)](P for interaction = 0.08).
Conclusions: Higher OCM nutrient intake is inversely associated with PD risk.
Front Psychiatry. 2025 Aug 19:16:1569826. Exploring neuropsychiatric manifestations of vitamin B complex deficiencies
Abstract
B complex vitamins, a group of eight water-soluble vitamins, play interconnected roles in maintaining nervous system health. Thiamine (B1), riboflavin (B2), and niacin (B3) are essential as co-enzymes in numerous metabolic reactions related to energy production. Thiamine is involved in the Krebs cycle, riboflavin in the electron transport chain, and niacin plays a key role in both glycolysis and the Krebs cycle. These metabolic processes are vital for sustaining the integrity of the nervous system, as the energy produced is critical for the functioning of nerve cells.
Deficiencies in these vitamins can lead to significant neurological and psychiatric conditions, including Wernicke Korsakoff syndrome, Parkinson’s disease, and various mental illnesses.
Additionally, pyridoxine (B6), folate (B9), and cobalamin (B12) are indispensable coenzymes for the methylation of homocysteine to methionine, a process critical to nervous system function. Elevated homocysteine levels, resulting from deficiencies of these vitamins, are associated with higher risks of depression and dementia.
Imbalances in these vitamins can disrupt key biochemical pathways, leading to neuropsychiatric disorders. The literature reviewed underscores the importance of daily intake of B complex vitamins to maintain normal serum levels and optimal neuronal function. This review aims to elucidate the neuropsychiatric manifestations associated with deficiencies in these vitamins.
J Neural Transm (Vienna). 2024 Dec;131(12):1495-1509. Parkinson’s disease and vitamins: a focus on vitamin B12
Abstract
Parkinson’s disease (PD) has been linked to a vast array of vitamins among which vitamin B12 (Vit B12) is the most relevant and often investigated specially in the context of intrajejunal levodopa infusion therapy. Vit B12 deficiency, itself, has been reported to cause acute parkinsonism. Nevertheless, concrete mechanisms through which B12 deficiency interacts with PD in terms of pathophysiology, clinical manifestation and progression remains unclear.
Recent studies have suggested that Vit B12 deficiency along with the induced hyperhomocysteinemia are correlated with specific PD phenotypes characterized with early postural instability and falls and more rapid motor progression, cognitive impairment, visual hallucinations and autonomic dysfunction. Specific clinical features such as polyneuropathy have also been linked to Vit B12 deficiency specifically in context of intrajejunal levodopa therapy.
In this review, we explore the link between Vit B12 and PD in terms of physiopathology regarding dysfunctional neural pathways, neuropathological processes as well as reviewing the major clinical traits of Vit B12 deficiency in PD and Levodopa-mediated neuropathy.
Finally, we provide an overview of the therapeutic effect of Vit B12 supplementation in PD and posit a practical guideline for Vit B12 testing and supplementation.
Neurol Res. 2014 Dec;36(12):1121-8. Involuntary movements due to vitamin B12 deficiency
Abstract
Deficiency of vitamin B12 produces protean effects on the nervous system, most commonly neuropathy, myelopathy, cognitive and behavioural symptoms, and optic atrophy. Involuntary movements comprise a relatively rare manifestation of this readily treatable disorder. Both adults and infants deficient in vitamin B12 may present with chorea, tremor, myoclonus, Parkinsonism, dystonia, or a combination of these, which may precede diagnosis or become apparent only a few days after parenteral replacement therapy has begun. The pathogenesis of these movement disorders shows interesting parallels to certain neurodegenerative conditions.
The clinical syndrome responds well to vitamin B12 supplementation in most cases, and an early diagnosis is essential to reverse the haematological and neurological dysfunction characteristic of this disorder.
We elucidate the association of vitamin B12 deficiency with movement disorders in adults and in infants, discuss the pathogenesis of this association, review previously reported cases, and present a young adult male with severe generalized chorea that showed a salutary response to vitamin B12 supplementation.
Robert Rodgers PhD
Founder 2004
Parkinsons Recovery ®
https://www.parkinsonsrecovery.com




Leave a Reply